Form D · Pharmaceuticals
SEQUELLA INC.
Rockville, MD · CIK 0001065544
Offering snapshot reported Oct 10, 2017 · SEC filing
- Reported sold
- $631K Offering amount: $3.62M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $25.1K Reported outside-investor minimum
- First sale
- Sep 7, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 10, 2017 | Initial | $630,589 | No comparison | 6 | SEC filing |
| Sep 22, 2016 | Initial | $940,942 | No comparison | 9 | SEC filing |
| Sep 22, 2016 | Initial | $1,724,250 | No comparison | 9 | SEC filing |
| Oct 10, 2014 | Initial | $3,100,000 | No comparison | 36 | SEC filing |
| Oct 1, 2013 | Initial | $555,000 | No comparison | 3 | SEC filing |
| Sep 4, 2012 | Initial | $100,000 | No comparison | 2 | SEC filing |
| Nov 4, 2011 | Initial | $50,000 | No comparison | 2 | SEC filing |
| Aug 10, 2011 | Initial | $550,000 | No comparison | 5 | SEC filing |
| Jun 2, 2011 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Feb 22, 2010 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| Aug 20, 2009 | Initial | $1,500,000 | No comparison | 4 | SEC filing |
| Jul 9, 2009 | Initial | $720,097 | No comparison | 1 | SEC filing |
| Aug 29, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Aug 29, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 12, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 31, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 11, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 30, 2006 | Paper | Not reported | No comparison | Not reported | |
| May 12, 2006 | Paper | Not reported | No comparison | Not reported | |
| Apr 21, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jan 6, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 23, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $42.8K
- Finders' fees
- $0
- Form D file number
- 021-296216
Offering amount includes warrant compensation noted in Item 15.
SALES COMMISSIONS PAID TO LAMPOST CAPITAL INCLUDE CASH PAYMENT OF $20,313.00, WARRANTS FOR COMMON STOCK SHARES WITH AN AGGREGATE EXERCISE PRICE OF $14,469.00 AND $8,000.00 IN EXPENSES
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| LAMPOST CAPITAL, L.C. | 43706 | DAVID N. OLSON · CRD 4765634 |
Source: Form D, filed Oct 10, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Leo Einck | Director, Executive |
| John Friedman | Director |
| Gary Horwith | Executive |
| William Hoskins | Director |
| Alan Klein | Executive |
| Kenneth Lynn | Director |
| Paige Macdonald | Director |
| Paige Mac Donald | Director |
| David Mcneeley | Executive |
| Ronald I. Meltzer | Director |
| Lawrence Miller | Executive |
| Carol A. Nacy | Director, Executive |
| Mark Rampy | Executive |
| Bradley Rotter | Director |
| Martin M Zug | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
9610 Medical Center Dr Suite 200
Rockville, MD, 20850
Rockville, MD, 20850